Alcon’s AcrySof IQ Vivity and Clareon Vivity extended depth of focus (EDOF) intraocular lenses (IOLs) have surpassed more than one million implants worldwide.
Vivity is said to be the most implanted EDOF IOL globally¹, with Australian ophthalmologists claiming it has filled a gap in the presbyopia-correcting (PC-IOL) market since it’s local launch in September 2020 by offering an alternative option to patients who weren’t suitable for a diffractive IOL.
Local surgeons say it represents a major advance in the premium IOL category by offering excellent distance, intermediate and functional near vision, with a monofocal-like visual disturbance profile.
“We are proud to celebrate the one million Vivity eyes empowering cataract patients to see the world with high quality vision from distance to functional near—day and night,” Mr Sean Clark, global surgical franchise president at Alcon, said.
“This milestone embodies our commitment to addressing the diverse vision needs of today’s patients, who desire less dependence on glasses post-surgery and low visual disturbances, with a game-changing presbyopia-correcting intraocular lens (PC-IOL) option that expands the patient candidacy pool.”
Vivity uses Alcon’s patented non-diffractive Wavefront-Shaping X-WAVE technology, an optical principle that simultaneously stretches and shifts light without splitting it to balance quality of vision and maximise range of vision.2,3
The optic is said to deliver optimal distance and intermediate vision, as well as functional near vision.² The mechanism of action is not refractive, does not introduce spherical aberrations and is said to have expanded PC-IOL access to even more patients.
Alcon said Vivity is designed to simplify presbyopia correction, prioritising patient satisfaction while minimising surgeon and clinic chair time.
Recent, large-scale real-world data has demonstrated high patient satisfaction of Vivity among several patient cohorts. The Vivity registry study4-6 included patients with common mild comorbidities like glaucoma, dry eye, and retinopathy/maculopathy, as well as post-refractive eyes. Ninety-two percent of patients reported satisfaction with their sight, and more than 91% reported no haloes, glares, or starbursts.
More reading
How Alcon’s Vivity is disrupting the Australian IOL landscape
Alcon launches breakthrough Vivity IOL in Australia
References
1.Market Scope – 2023 Premium Cataract Surgery Market Report; 2023 IOL Market Report.
2. Alcon Data on File; U.S. Pat. Nos. RE45,969, 9,968,440, 11,083,566.
3. AcrySof IQ Vivity or Clareon Vivity IOL Directions for Use.
4. Reus NJ, Kooijman M, Perez-Vives C. Overall Visual Outcomes from a Real-world Study of Presbyopia-correcting IOLs in a Large Population. Presented at the European Society of Cataract and Refractive Surgery (ESCRS) Annual Meeting; 8-12 Sept. 2023; Vienna, Austria.
5. Alcon Data on File, 2024. REF-22137.
6. Alcon IOL Global Sales; Jan. 2021-Nov. 2022.
